About Pharma Industry

BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.

Why J&J's $1.7B Win in Abbott Humira Case May be Garbage

By Jim Edwards | Jun 30, 2009

Abbott Labs‘ management is probably not worrying too much about the $1.7 billion damages award made in favor of Johnson & Johnson’s Centocor unit for Humira’s infringement on the latter’s Remicade patents. (It wasn’t worried enough to put out a press statement, for instance.)

That’s because the court that awarded the damages is a famous judicial hellhole. The patent court of the U.S. District Court in the Eastern District of Texas, presided over by Judge T. John Ward (pictured), has been unfavorably compared to the court in My Cousin Vinny.

You might be wondering why a case between New Jersey’s J&J and Illinois’ Abbott was being decided in Marshall, Texas, pop. 24,000, the “Pottery Capital of the World” and home of the “Fire Ant Festival.” This Technology Review story gives the answer:

… patent plaintiffs whose cases go to trial in Marshall win 88 percent of the time, according to research firm Legalmetric, compared with 68 percent nationwide.

While those odds still favor J&J’s win, there’s a 1 in 5 chance that the court has gotten it “wrong,” if you assume that the nationwide average is “right.”* Thus Marshall has long been known as a patent troll filing place, where trials are speeded up and the court decides in favor of the holder, usually the plaintiff. Tech Review again:

In the rough calculus of intellectual property litigation, tough judges equate with speedy cases — and that’s exactly what you want if you’re a plaintiff with limited cash, but potentially big-time settlement payments or damages from a company you claim is infringing on your patent.

Judge Ward, who decided this case, sits on an average of 23 patent cases a year. That would be a staggering workload in a normal federal court, except that a look at the docket in Centocor Inc. v. Abbott Laboratories, 07cv139, shows just 261 documents filed in the case, including the jury notes and verdict. Federal trials in pharma matters often reach thousands of filings before a trial starts. Not in Ward’s court, where everything’s kept simple so the good folk of Texas can understand it. (If lawyers in Ward’s court argue too much, they get “the rattlesnake speech.”)

J&J’s amended complaint in the case was just eight pages. Abbott’s reply was 12. The latter’s construction claim brief, featuring its pretrial legal arguments, was a comparatively Dr. Zhivago-like 35 pages. Did that, possibly, test Ward’s patience?

*Is my math wrong? Use the comments section to let me know.

Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.

BNET User Analysis

Web Buzz:
  • Abbott ordered to pay J&J $1.67 billion in US TNF patent case$

    Scrip News - 145 days 10 hours 19 minutes ago

    A federal jury in Texas has held Abbott liable for nearly $1.7 billion in damages for wilful infringement of a patent held by Johnson & Johnson's Centocor subsidiary covering anti-TNF technology. Abbott's product Humira (adalimumab) was

  • Abbott loses $1.67B patent fight to J&J$

    Fierce Pharma - 146 days 11 hours 38 minutes ago

    It's the patent judgment to end all patent judgments. A federal jury in Texas said Abbott Laboratories should pay some $1.7 billion to Johnson & Johnson for copycatting its blockbuster rheumatoid arthritis drug Remicade. J&J's Centocor subsidiary had alleged that Abbott's Humira was made with technology J&J exclusively licensed from New York...

  • Abbott to pay J&J $1.67 billion in patent case$

    MarketWatch - 146 days 12 hours 4 minutes ago

    A federal court in Texas has ordered Abbott Laboratories to pay Johnson & Johnson $1.67 billion in damages for patent infringement. Abbott plans an appeal of the jury verdict.

  • U.K. trust sues for Enbrel royalties

    Fierce Pharma - 25 days 10 hours 49 minutes ago

    Can a British trust patent a treatment approach? The Mathilda and Terence Kennedy Institute of Rheumatology Trust thinks so. It has sued Amgen and Wyeth, seeking royalty payments for their arthritis drug Enbrel, Reuters reports. According to its court complaint, the trust holds a 2001 patent that relates to treating arthritis with a combination...

  • Bayer Sues Abbott Over Humira

    Wall Street Journal - 327 days 20 hours 36 minutes ago

    Bayer filed a patent-infringement lawsuit in federal court against Abbott Laboratories relating to the autoimmune drug Humira, which is Abbott's top-selling product

 
Reply to Story

BNET TalkbackShare your ideas and expertise on this topic

Subscribe to this discussion via Email or RSS

  •  
    1

    Manabozho

    07/01/09 | Report as spam

    Judging Judge Ward

    The problem isn?t so much with the arithmetic (though that?s squirrelly too) as with the underlying logic. You compare outcomes of one trial court with the national-average outcomes of trial courts. However, this implies nothing at all about the likelihood of reversal, which takes place in a separate system?the courts of appeals. To make a meaningful assertion about that, you?d need to know how often Judge Ward?s patent-case decisions are appealed, and what ratio are upheld vs overturned. That?s the mechanism by which Johnson and Johnson would get a reversal, and Abbott a reprieve, and it bears no necessary resemblance to the raw data from the trial courts. There are 94 judicial districts, but only 12 federal courts of appeals.

    Back to the math: plaintiffs' odds of a favorable outcome are improved 29.4 % in this jurisdiction. Arrive at this by comparing the national average to the record of this particular court--ie, you had 68 chances in 100 of prevailing in a randomly chosen US court. Your 88 chances in 100 of prevailing as a plaintiff in Judge Ward's court represent a 29.4% uptick in your favor, versus the 68 you had ?at random.?

    Thanks for inviting comment. It goes to a theme in this column--the danger of creating or paraphrasing scientific / quantitative inferences. The odds that an innocent effort to "make it more interesting" will result in an accurate statement, or a fastidious equivalent to someone else's quantitative or scientific statement, are not good. (Sorry, don't have statistics on that probability.)

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here